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other pathological manifestations, under conditions where the oxi-
dative phosphorylation system is limiting or unavailable e.g. due
to inhibition by toxins, metabolic overload or genetic ablation of
one or more of its components. The alternative enzymes are non-
proton-motive, and are typically composed of just a single
polypeptide, in contrast to the highly complex enzymes of the
oxidative phosphorylation system. Vertebrates lack the alternative
enzymes, leading to the idea that we could alleviate respiratory
chain dysfunction such as those which occurs in pathological states,
by expressing genes for these enzymes therapeutically or even
prophylactically in humans. To this end, we have set about
transferring the relevant genes to model organisms, using as our
source material the urochordate Ciona intestinalis, a representative
of the group of organisms phyletically closest to the vertebrates,
but which has retained the alternative enzymes over the course of
evolution. The Ciona alternative oxidase (AOX) can be expressed in
both Drosophila and the mouse throughout the life cycle and across
a wide range of tissues. Under standard conditions, it contributes
hardly at all to mitochondrial electron ﬂow, does not interfere with
the oxidative phosphorylation system, and appears to cause no
signiﬁcant deleterious effects. However, under stress conditions,
including both acute and chronic exposures to respiratory toxins,
genetic deﬁciency of cytochrome oxidase, or treatments that create or
potentiate overproduction of ROS, AOX can alleviate pathological
phenotypes in cells, ﬂies and in mice. If safe and efﬁcient delivery of
AOX can be achieved, it has enormous potential as a wide-spectrum
therapy for conditions associatedwith primary or secondarymitochon-
drial dysfunction.
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We have established the genotype–phenotype correlations for
the complete spectrum of POLG syndromes, by reﬁning our pre-
viously described protocol for mapping pathogenic mutations in the
human POLG gene to functional clusters in the catalytic core of the
mitochondrial replicase, Pol γ. We assigned 136 mutations to ﬁve
clusters and identify segments of primary sequence that can be used
to delimit the boundaries of each cluster. We report that compound
heterozygous patients with two mutations from different clusters
manifested more severe, earlier onset POLG syndromes, whereas two
mutations from the same cluster are less common and generally are
associated with less severe, later onset POLG syndromes. We also
show that speciﬁc cluster combinations are more severe than others,
and have a higher likelihood to manifest at an earlier age. Our
clustering method provides a powerful tool to predict the pathogenic
potential and predicted disease phenotype of novel variants and muta-
tions in POLG, the most common nuclear gene underlying mitochon-
drial disorders. We propose that such a prediction tool would be useful
for routine diagnostics for mitochondrial disorders.
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Reactive oxygen species (ROS) are toxic to the cells and theremust be
speciﬁc defense mechanism in the cells to alleviate oxidative stress. The
primarily responsible enzyme for this reaction is the Alkylhydroperoxide
Reductase (AhpR) enzyme, consisting of the 57 kDa ﬂavo protein AhpF
(PrxR) expressed only by eubacteria and the 21 kDa AhpC (Prx) protein
expressed in all kingdoms [1,2]. The reduction of peroxides occurs via
the redox active disulphide center of AhpC, whose reduced state
becomes restored by AhpF, which transfers electrons from NADH onto
AhpC. AhpF consists of three domains; thioredoxin (Trx) like N-terminal
domain (NTD) attached to the thioredoxin reductase (TrxR) like C-
terminal portion containing FAD- and NADH-binding domains. The
proposed catalytic turnover of AhpFmay requiremajor domainmotions,
analogous to those deduced from bacterial Trx/TrxR system [3]. Here we
are presenting for ﬁrst time the crystal structure of E. coli AhpF complex
with its substrate NADH at 2.5 Å resolution [4]. The structure reveals
the basis of its substrate speciﬁcity for NADH over NADPH. In addition,
it implies the alternating conformation required for the C-terminal
NADH-binding domain to bring a bound NADH to the re-face of the
isoalloxazine ring of ﬂavin, and enabling the electron transfer to occur as
well as the oxidation of NADH-domain dithiol via the redox active
disulphide centre of the NTD. The detailed structural model will open
future research opportunities to design selective drug against bacterial
AhpF as potential target.
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